Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs13266634
rs13266634
1.000 GeneticVariation BEFREE The current study demonstrated a modest but significant effect of SLC30A8 (rs13266634) polymorphisms on T2D predisposition. 31823921

2019

dbSNP: rs9939609
rs9939609
FTO
0.900 GeneticVariation BEFREE For the rs9939609 variant (FTO), the dominant model AA/(AT+TT) revealed significant association with T2D [odds ratio (OR)=2.03, P=0.021], but was non-significant post correction for multiple testing (P=0.002). 31823921

2019

dbSNP: rs7903146
rs7903146
0.900 GeneticVariation BEFREE Interestingly, the highest level of adropin was detected in T2DMpatients with rs7903146T/T genotype.<b>Conclusion:</b> Our analysis showed higher level of adropin in T2DM patients and increased risk of T2DM with rs7903146T/T and rs7903146C/T genotypes. 31818149

2019

dbSNP: rs7903146
rs7903146
0.900 GeneticVariation BEFREE Interestingly, the highest level of adropin was detected in T2DMpatients with rs7903146T/T genotype.<b>Conclusion:</b> Our analysis showed higher level of adropin in T2DM patients and increased risk of T2DM with rs7903146T/T and rs7903146C/T genotypes. 31818149

2019

dbSNP: rs7903146
rs7903146
0.900 GeneticVariation BEFREE Adropin peptide may have roles in T2DM pathogenesis due to several roles in glucose tolerance, decrement of insulin resistance, lipid metabolism and energy homoeostasis.<b>Aim:</b> To evaluate the serum level of adropin in T2DM patients and comparing with healthy individuals as well as assessing frequency of rs7903146 genotypes/alleles in patients and control groups.<b>Methods:</b> We analysed the frequency of rs7903146 genotypes/alleles in 93 patients with T2DM disease and 53 healthy individuals by the method of polymerase chain reaction-restriction fragment length polymorphism analysis. 31818149

2019

dbSNP: rs3758391
rs3758391
0.030 GeneticVariation BEFREE The polymorphisms rs3758391 and rs1800470 located in SIRT1 and TGF-β1 have been associated with type 2 diabetes in different populations but its functional effect is not clear. 31799723

2020

dbSNP: rs1800470
rs1800470
0.020 GeneticVariation BEFREE The polymorphisms rs3758391 and rs1800470 located in SIRT1 and TGF-β1 have been associated with type 2 diabetes in different populations but its functional effect is not clear. 31799723

2020

dbSNP: rs10830963
rs10830963
0.900 GeneticVariation BEFREE These data suggest that the <i>MTNR1B</i> rs10830963 and rs1387153 polymorphisms are associated with repaglinide monotherapy efficacy in Chinese patients with T2DM. 31787898

2019

dbSNP: rs1387153
rs1387153
0.880 GeneticVariation BEFREE These data suggest that the <i>MTNR1B</i> rs10830963 and rs1387153 polymorphisms are associated with repaglinide monotherapy efficacy in Chinese patients with T2DM. 31787898

2019

dbSNP: rs7873784
rs7873784
0.020 GeneticVariation BEFREE We hypothesize that additional functional PU.1 site may increase TLR4 expression in individuals carrying minor C variant of rs7873784 and modulate the development of certain pathologies, such as rheumatoid arthritis and type-2 diabetes mellitus. 31785408

2020

dbSNP: rs7903146
rs7903146
0.900 GeneticVariation BEFREE Our results provide evidence that genetic variation in <i>TCF7L2</i> rs7903146 could increase risk for peripheral arterial disease in patients exhibiting long-standing type 2 diabetes. 31775533

2020

dbSNP: rs11254375
rs11254375
0.010 GeneticVariation BEFREE Permutation analysis associated rs11254375_G/T (p<sub>emp</sub> = 0.00049, OR = 1.482), rs6602175_G/T (p<sub>emp</sub> = 0.016, OR = 0.822), rs1801224_G/T (p<sub>emp</sub> = 0.025, OR = 0.830), rs4366393_A/G (p<sub>emp</sub> = 0.028, OR = 0.829) and rs7071576_A/G (p<sub>emp</sub> = 0.04, OR = 1.219) with T2DM. 31770575

2020

dbSNP: rs1801224
rs1801224
0.010 GeneticVariation BEFREE Permutation analysis associated rs11254375_G/T (p<sub>emp</sub> = 0.00049, OR = 1.482), rs6602175_G/T (p<sub>emp</sub> = 0.016, OR = 0.822), rs1801224_G/T (p<sub>emp</sub> = 0.025, OR = 0.830), rs4366393_A/G (p<sub>emp</sub> = 0.028, OR = 0.829) and rs7071576_A/G (p<sub>emp</sub> = 0.04, OR = 1.219) with T2DM. 31770575

2020

dbSNP: rs4366393
rs4366393
0.010 GeneticVariation BEFREE Permutation analysis associated rs11254375_G/T (p<sub>emp</sub> = 0.00049, OR = 1.482), rs6602175_G/T (p<sub>emp</sub> = 0.016, OR = 0.822), rs1801224_G/T (p<sub>emp</sub> = 0.025, OR = 0.830), rs4366393_A/G (p<sub>emp</sub> = 0.028, OR = 0.829) and rs7071576_A/G (p<sub>emp</sub> = 0.04, OR = 1.219) with T2DM. 31770575

2020

dbSNP: rs6602175
rs6602175
0.010 GeneticVariation BEFREE Permutation analysis associated rs11254375_G/T (p<sub>emp</sub> = 0.00049, OR = 1.482), rs6602175_G/T (p<sub>emp</sub> = 0.016, OR = 0.822), rs1801224_G/T (p<sub>emp</sub> = 0.025, OR = 0.830), rs4366393_A/G (p<sub>emp</sub> = 0.028, OR = 0.829) and rs7071576_A/G (p<sub>emp</sub> = 0.04, OR = 1.219) with T2DM. 31770575

2020

dbSNP: rs7071576
rs7071576
0.010 GeneticVariation BEFREE Permutation analysis associated rs11254375_G/T (p<sub>emp</sub> = 0.00049, OR = 1.482), rs6602175_G/T (p<sub>emp</sub> = 0.016, OR = 0.822), rs1801224_G/T (p<sub>emp</sub> = 0.025, OR = 0.830), rs4366393_A/G (p<sub>emp</sub> = 0.028, OR = 0.829) and rs7071576_A/G (p<sub>emp</sub> = 0.04, OR = 1.219) with T2DM. 31770575

2020

dbSNP: rs1111875
rs1111875
0.900 GeneticVariation BEFREE Multivariate model analysis, including T2D status, age, and body mass index (BMI), displayed significant covariance in PPARGC-1α rs8192678; SIRT1 rs7896005; TCF7L2 rs7903146 and rs122243326; UCP3 rs3781907; and HHEX rs1111875 with a P < 0.05. 31759989

2020

dbSNP: rs7903146
rs7903146
0.900 GeneticVariation BEFREE Multivariate model analysis, including T2D status, age, and body mass index (BMI), displayed significant covariance in PPARGC-1α rs8192678; SIRT1 rs7896005; TCF7L2 rs7903146 and rs122243326; UCP3 rs3781907; and HHEX rs1111875 with a P < 0.05. 31759989

2020

dbSNP: rs8192678
rs8192678
0.100 GeneticVariation BEFREE Multivariate model analysis, including T2D status, age, and body mass index (BMI), displayed significant covariance in PPARGC-1α rs8192678; SIRT1 rs7896005; TCF7L2 rs7903146 and rs122243326; UCP3 rs3781907; and HHEX rs1111875 with a P < 0.05. 31759989

2020

dbSNP: rs7896005
rs7896005
0.030 GeneticVariation BEFREE Multivariate model analysis, including T2D status, age, and body mass index (BMI), displayed significant covariance in PPARGC-1α rs8192678; SIRT1 rs7896005; TCF7L2 rs7903146 and rs122243326; UCP3 rs3781907; and HHEX rs1111875 with a P < 0.05. 31759989

2020

dbSNP: rs3781907
rs3781907
0.020 GeneticVariation BEFREE Multivariate model analysis, including T2D status, age, and body mass index (BMI), displayed significant covariance in PPARGC-1α rs8192678; SIRT1 rs7896005; TCF7L2 rs7903146 and rs122243326; UCP3 rs3781907; and HHEX rs1111875 with a P < 0.05. 31759989

2020

dbSNP: rs10830963
rs10830963
0.900 GeneticVariation BEFREE While marginal evidence of interaction between self-reported morningness-eveningness preference and rs10830963 in risk of type 2 diabetes was seen, this interaction did not persist when analysis was expanded to include all participants regardless of employment status and when accelerometer-derived sleep midpoint was used as an objective measure of morningness-eveningness preference. 31757795

2020

dbSNP: rs1501299
rs1501299
0.100 GeneticVariation BEFREE Thus, we concluded on the basis of observed results that the ADIPOQ gene polymorphisms rs822396 and rs1501299 plays an important role in the development of type 2 diabetes in North Indian Punjabi population. 31755094

2019

dbSNP: rs822396
rs822396
0.030 GeneticVariation BEFREE Thus, we concluded on the basis of observed results that the ADIPOQ gene polymorphisms rs822396 and rs1501299 plays an important role in the development of type 2 diabetes in North Indian Punjabi population. 31755094

2019

dbSNP: rs352165
rs352165
0.010 GeneticVariation BEFREE The meta-analysis between BD and T2D identified six significant SNPs, three of which were located in ALAS1 (best SNP: rs352165, p = 3.4E-08). 31754094

2019